Medivir AB
Lunastigen 7
Huddinge
141 44
Tel: 46-8-608-3100
Fax: 46-8-608-3199
Website: http://www.medivir.se/
Email: medivir@medivir.se
490 articles about Medivir AB
-
Medivir AB Release: Simeprevir Has Been Approved In Canada As A New Treatment For Hepatitis C
11/20/2013
-
Medivir AB Release: Results From the COSMOS Study With Simeprevir and Sofosbuvir in Cirrhotic and Non-Cirrhotic HCV genotype 1 Patients Presented at American Association for Study of Liver Diseases
11/5/2013
-
Medivir AB Announces That New Simeprevir Data Will be Presented at the American Association for Study of Liver Diseases Meeting
11/4/2013
-
Johnson & Johnson-Medivir AB's Drug Works Against Hepatitis C
10/23/2013
-
Medivir AB Announces Data From Two Phase 3 Studies With Simeprevir in Hepatitis C Subpopulations – HCV/HIV Co-Infected and Genotype 4 Infected Patients
10/18/2013
-
Medivir AB Nomination Committee Appointed
10/14/2013
-
Medivir AB: MIV-247 Has Been Selected as a Candidate Drug and Enters Development for the Treatment of Neuropathic Pain
10/10/2013
-
Medivir AB Release: MIV-247 Has Been Selected as a Candidate Drug and Enters Development for the Treatment of Neuropathic Pain
10/10/2013
-
Medivir AB Release: Positive Results From a Phase I Study With MIV-711 for the Treatment of Osteoarthritis and Other Bone Related Disorders
10/9/2013
-
Medivir AB: Simeprevir Data From Cosmos Study in Hepatitis C Patients Will be Presented as Late-Breaking Presentation at American Association for Study of Liver Diseases
10/7/2013
-
Medivir AB Release: Simeprevir Data From COSMOS Study in Hepatitis C Patients Will be Presented as Late-Breaking Presentation at American Association for Study of Liver Diseases
10/7/2013
-
Medivir AB Announces that Simeprevir Data Will be Presented at the Upcoming American Association for Study of Liver Diseases Meeting
10/1/2013
-
Medivir AB Announces That Simeprevir Data Will be Presented at the Upcoming American Association for Study of Liver Diseases Meeting
10/1/2013
-
Medivir AB's Simeprevir Has Been Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C Infection
9/27/2013
-
Medivir AB Capital Markets Day on 10 October 2013
9/18/2013
-
Ferrer Internacional and Medivir AB Enter Agreement for Commercializing a New Treatment for Agitation Associated With Schizophrenia and Bipolar Disease in the Nordics
9/18/2013
-
Medivir AB: The Regulatory Process in Japan for Simeprevir
9/17/2013
-
Medivir AB, Daewoong Pharmaceutical Co., Ltd. Discontinue Hepatitis B Drug Development
9/6/2013
-
Medivir AB Announces Interim Results From Cohort 2 of the COSMOS Study Evaluating Simeprevir and Sofosbuvir in HCV Patients With METAVIR Scores F3-F4
8/28/2013
-
Medivir AB Announces Interim Results From Cohort 2 of the COSMOS Study Evaluating Simeprevir and Sofosbuvir in HCV Patients With METAVIR Scores F3-F4
8/28/2013